COMP360 psilocybin treatment in TRD

COMP360 psilocybin treatment in TRD presents results from a randomised controlled phase 2b study of investigational psilocybin treatment for treatment-resistant depression. According to the source page, the trial was the largest psilocybin treatment clinical trial ever conducted, with 233 patients across 22 sites in 10 countries across Europe and North America. The study assessed safety and efficacy across three doses: 1mg, 10mg, and 25mg. The published results reported that a single 25mg dose of COMP360 psilocybin, combined with psychological support, was associated with a statistically significant reduction in depressive symptoms after three weeks, with a rapid and durable response for up to 12 weeks. The content is informational and research-focused rather than a training course. It appears most relevant to clinicians, researchers, and others following clinical trial evidence in psychedelic medicine and treatment-resistant depression.